Background. Isavuconazole (ISA) is a once-daily, extended-spectrum triazole approved for treatment of invasive aspergillosis and mucormycosis. The pharmacokinetic profile, daily dosing, lack of therapeutic drug monitoring (TDM) and reduced cost make ISA a promising option for use as prophylaxis for invasive fungal infections (IFIs). We report our experience with use of ISA for prophylaxis of IFI in high-risk hematologic malignancy patients.
Session: 168. Stewardship: Improving Outcomes Friday, October 6, 2017: 12:30 PM Background. A key part of our antimicrobial stewardship program (ASP) includes interdisciplinary collaboration to develop a transition of care plan for patients needing long-term antibiotics. Many of our challenging clinical scenarios involve inpatients, who do not qualify for intravenous antibiotics administered via home health agencies or skilled nursing facilities, with complicated skin and soft tissue structure (cSSTI), joint and bone infections. Their cost-of-care, driven mainly by prolonged length of stay (LOS), is high. For infections involving gram-positive bacteria treatment with dalbavancin, while an expensive antibiotic, posed a viable option for transitioning select patients for early discharge.
Methods. Retrospective review of cases was conducted for all patients administered dalbavancin at Deaconess Hospital from Dec 2015 to Jan 2017. Prior to drug administration patient cases required approval by ASP for appropriateness of treatment plan. Data collected included diagnosis/site of infection, organism, current IVDU, treatment plan (and if completed), inpatient and estimated total LOS, dalbavancin dosing regimen, and cost (drug and LOS). Overall cost savings was calculated by LOS savings ($1,000/day) minus cost of dalbavancin ($1,400/500mg vial).
Results. 17 patients (13 IVDUs) were administered dalbavancin: 8 for cSSTI, 8 for osteo/joint infections and 1 for bacteremia. 7 of 8 patients with cSSTI received either 1 or 1.5 gm of dalbavancin once; and 1 patient returned for weekly dosing to complete therapy. 3 of 8 patients with osteo/joint infections received a one-time dose to complete treatment; 4 returned for weekly dosing; and 1 patient was lostto-follow-up. Only one patient, overall, was readmitted. Treatment was well tolerated and no complications were noted. Mean actual LOS (range) for patients with cSSTI was 11 (3-32) days; and with osteo/joint was 23 (13-36) days. Cost of dalbavancin was $68,600. Total LOS was decreased by 270 days. Overall savings were over $200,000.
Conclusion. Findings were presented to pharmacy and hospital leadership as an example of a safe, effective, cost-saving ASP outcome. For every dollar spent on dalbavancin our hospital saved three dollars on cost-of-care related to decreased length of stay.
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Impact of a Standardized Penicillin Allergy Assessment Program to Optimize Penicillin Allergy Documentation and Β-lactam Antibiotic Use at an Academic Medical Center
Background. The 2016 IDSA Guidelines for Implementing an Antibiotic Stewardship Program recommend that Antibiotic Stewardship Programs (ASPs) implement allergy assessments for patients with a documented penicillin allergy. The impact of completing these allergy assessments on allergy documentation and antibiotic prescribing is not well characterized.
Methods. We performed a retrospective quasi-experimental study to evaluate the impact of the implementation of a standardized penicillin allergy assessment program by the Duke Antimicrobial Stewardship and Evaluation Team (ASET). Starting in May 2015, pharmacy technicians performed detailed assessments of admitted patients with a documented penicillin allergy; assessments were reviewed by clinical pharmacists. The pre-intervention period included randomly-selected adult patients with a reported penicillin allergy admitted from May 2014 to April 2015. The primary study outcome was accurate characterization of penicillin allergy within the electronic health record (EHR), including clarification of allergic reaction and removal of allergy. Secondary outcomes included B-lactam use within 90 days of hospitalization, time to complete the assessments, and hospital-wide aztreonam use, measured as days of therapy (DOT) per 1000 days present.
Results. A total of 200 patients were included; 100 patients during the intervention period, and 100 during the pre-intervention period. The proportion of patients who had their allergy information updated increased from 31% to 62% following implementation of the program (P < 0.0001); inappropriate allergy documentation was removed in 7 (7%) patients. The program did not change the percentage of study patients who received a B-lactam (24% vs. 26%; P = 0.74). Hospital-wide aztreonam use was lower in the intervention group (10.8 vs. 7.0 DOT/1,000 days present; P < 0.0001). The average time to perform each assessment was 15 minutes.
Conclusion. Implementation of a standardized penicillin allergy assessment program led to a significant impact on allergy documentation within the EHR without burdening pharmacy staff. While the rate of B-lactam therapy was unchanged, we observed a significant decrease in aztreonam utilization after program implementation. 
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